middle.news
Recce Pharmaceuticals Expands Phase 3 Trial with Active Comparator in Diabetic Foot Infections
11:02am on Wednesday 19th of August, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Expands Phase 3 Trial with Active Comparator in Diabetic Foot Infections
11:02am on Wednesday 19th of August, 2026 AEST
Key Points
HREC approves active-controlled, non-inferiority arm in Phase 3 DFI trial
208 patients to be randomised between R327G and physician-selected antibiotics
Multiple efficacy assessments per participant to deepen clinical data
Wound imaging introduced for objective infection measurement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE